2The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Work-shop Group.Revised 2003 consensus on diagnosis criteria and longterm health risks related to polycystic ovary syndrom(PCOS)[J].Hum Reprod,2004,19(1):41-47.
4Fruzzeti F,Berris C,Parrini D.Treatment of Hirsutisn:comp-arisons between different antiandrogens with central and perip-heral effects[J].Fertil Steril,1997,71(3):445.
5Glueck CI,Wang P,Goldenberg N,et al.Pregancy outcomes among women with polycystic ovary syndrome treated with me-tformin[J].Hum Reprod,2002,17(11):2858-2864.
6Glueck CI,Wang P,Koboyashi S,et al.Metform in therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome[J].Fertil Steril,2002,77(3):520-525.
7Pasquali R,Gambineri A.Insulin-sensitizing agents in polycystic ovary syndrome[J].Eur J Endocrinol,2006,154(6):763-775.
8Glueck CJ,Moreira A,Goldenberg N,et al.Pioglitazone and metform in in obese women with polycystic ovary syndrome not optimally responsive to metformin[J].Hum Reprod,2003,18(8):1618-1625.
9Risquez F.Induction of follicular growth and ovulation with uri-nary and recombinant gonadotropins[J].Reprod Biomed Online,2001,3(1):54-72.
10Ishimaru T, Okamoto S, Kajimura H, et al. Monitoring of follicles by ultrasonography during induction with HMGHCG treatment-especiallyon the prevention of side effects. Nippon Sanka Fujinka Gakkai Zasshi, 1985, 37(5):721-9.
5RAUTIO K, TAPANAINEN J S, RUOKONEN A, et al. Endocrine and metabolic effects of rosiglitazone in overweight women with PCOS: a randomized placebo-controlled study [ J ]. Human Repro- duction ( Oxford, England), 2006,21 (6) : 1400-1407.
6AZZIZ R. Controversy in clinical endocrinology: diagnosis of poly- cystic ovarian syndrome: the Rotterdam criteria are premature[ J]. The Journal of Clinical Endocrinology and Metabolism, 2006, 91 (3) :781-785.
